Corporate Updates

Cipla to acquire 11.71% stake in Wellthy Therapeutics


In a bid to acquire the minority stake in the Mumbai-based firm for a cash consideration of Rs 10.5 crore, Goldencross Pharma, a wholly-owned subsidiary of Cipla, has signed an agreement.Cipla


Drug major CiplaNSE 0.81 % recently revealed that it has inked a pact to acquire 11.71 per cent stake in Wellthy Therapeutics.

It was revealed that as part of the agreement, the partners plan to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.

Also read: Medlife to open 750 retail pharmacies across country


A multi-lingual clinically-validated digital disease management platform will be made available, as per the agreement,  to patients living with diabetes or cardiovascular diseases via doctors’ clinics or co-packaging on select Cipla brands.

The forum brings together behavioural science, real-world clinical evidence and artificial intelligence to provide real-time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

The transaction is expected to close before March 10.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top